Abstract
Clinical management of infective endocarditis (IE) is expected to become more difficult with the emergence of Staphylococcus aureus with reduced susceptibility to vancomycin (SARV) in the United States and worldwide. We report the strain characterization and treatment of a patient with SARV IE.
Publication types
-
Case Reports
-
Research Support, U.S. Gov't, Non-P.H.S.
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Anti-Bacterial Agents / pharmacology*
-
Anti-Bacterial Agents / therapeutic use
-
Endocarditis, Bacterial / drug therapy
-
Endocarditis, Bacterial / microbiology*
-
Humans
-
Male
-
Microbial Sensitivity Tests
-
Middle Aged
-
Staphylococcal Infections / drug therapy
-
Staphylococcus aureus / drug effects*
-
Treatment Failure
-
United States
-
Vancomycin / pharmacology*
-
Vancomycin / therapeutic use
-
Vancomycin Resistance*
Substances
-
Anti-Bacterial Agents
-
Vancomycin